JNJ-18038683

JNJ-18038683
Identifiers
	IUPAC name 1-benzyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[3,4-d]azepine;
CAS Number	851373-91-6;
PubChem CID	11151899;
ChemSpider	9327007;
UNII	28PGH5X4OQ;
Chemical and physical data
Formula	C20H20ClN3
Molar mass	337.85 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CNCCC2=C1C(=NN2CC3=CC=CC=C3)C4=CC=C(C=C4)Cl;
	InChI InChI=1S/C20H20ClN3/c21-17-8-6-16(7-9-17)20-18-10-12-22-13-11-19(18)24(23-20)14-15-4-2-1-3-5-15/h1-9,22H,10-14H2; Key:UKJPMZGILXATGT-UHFFFAOYSA-N;

JNJ-18038683 is a potent and selective antagonist of the 5HT₇ serotonin receptor discovered by Johnson & Johnson. It has nootropic and antidepressant effects in both animal and human studies and has progressed to Phase II trials as an adjunctive treatment for bipolar disorder, but it also has been found to reduce REM sleep and interfere with the circadian rhythm.[1][2]

References

Bonaventure P, Dugovic C, Kramer M, De Boer P, Singh J, Wilson S, et al. (August 2012). "Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder". The Journal of Pharmacology and Experimental Therapeutics. 342 (2): 429–40. doi:10.1124/jpet.112.193995. PMID 22570363. S2CID 10418102.
Shelton J, Yun S, Losee Olson S, Turek F, Bonaventure P, Dvorak C, et al. (2014). "Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity". Frontiers in Behavioral Neuroscience. 8: 453. doi:10.3389/fnbeh.2014.00453. PMC 4295543. PMID 25642174.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.